IL-11 has thus emerged as a novel cytokine driving STAT3-dependent intestinal tumorigenesis similarly to IL-6, and further investigation will help to evaluate its role as a diagnostic or therapeutic target for CRC. This evidence concerns the gene IL11 and colorectal carcinoma.